Navigation Links
New Drug Promising for Advanced Thyroid Cancer
Date:9/19/2010

By Steven Reinberg
HealthDay Reporter

FRIDAY, Sept. 17 (HealthDay News) -- A targeted drug called pazopanib could prove effective against difficult-to-treat cases of thyroid cancer cases, researchers say.

Most thyroid cancers can be treated with surgery or radioiodine, but about 5 percent of patients will develop an aggressive, life-threatening form of the disease.

Pazopanib (Votrient), already approved by the U.S. Food and Drug Administration for treating advanced kidney cancer, works by inhibiting growth of blood vessels essential for tumor growth and survival.

"Thyroid cancers, when they grow, they need to form a lot of blood vessels," explained researcher Dr. Julian Molina, an assistant professor of oncology at the Mayo Clinic and co-author of the study. "For blood vessels to grow, the growth factor VEGF is required, and the drug targets this protein," he said.

Not only does the drug block production of new blood vessels, it also interferes with the tumor cells' ability to continue growing, Molina said.

Pazopanib, a pill that's taken daily, doesn't have the severe side effects of standard chemotherapy, Molina said. But it is expensive. According to the U.S. Department of Health and Human Services, the average wholesale price, which is used to set drug reimbursements, is $6,595 a month.

For this phase 2 study, published in the Sept. 17 online edition of The Lancet Oncology, Molina and colleagues tested the efficacy and safety of pazopanib in 37 patients with advanced, rapidly progressing thyroid cancer.

About half of the patients --18 -- had a partial response to the drug, meaning their tumor shrank 30 percent or more, Molina said. None had a complete response, in which the tumor disappears completely, he added.

Twelve patients are still responding to the drug about a year later. "Patients take the drug until the drug is no longer effective," Molina said, noting these patients still take pazopanib every day.

Side effects were commonplace but typically mild. The most usual were diarrhea, hypertension, and an increase in a liver enzyme called aminotransferase. However, 15 patients had to have their dose lowered because of side effects, the researchers note.

The U.S. National Cancer Institute funded the study.

Molina noted that larger phase 3 trials will start soon, and he hopes the drug, made by GlaxoSmithKline, will be approved for treating advanced thyroid cancer.

"One of the goals in cancer care is to make cancer a chronic disease," Molina said. "If we can make cancer something like that, where your pills keep your disease controlled, that's a good goal," he said.

One expert said that any effective therapy would be welcome.

"There are not a lot of treatment options available for people with advanced thyroid cancer," said Dr. Leonard Lichtenfeld, deputy chief medical officer at the American Cancer Society.

While the study results will need to be replicated and tested against other treatment options before pazopanib can be approved as a therapy for thyroid cancer, he agreed that the drug shows promise.

"Targeted therapies are providing some effective treatment options for patients with diseases that traditionally have been difficult to treat," he said. "I find that very helpful and very exciting."

More information

For more information on thyroid cancer, visit the American Cancer Society.

SOURCES: Julian Molina, M.D., Ph.D., assistant professor of oncology, Mayo Clinic, Rochester, Minn.; Leonard Lichtenfeld, M.D., M.A.C.P., deputy chief medical officer, American Cancer Society, Atlanta; Sept. 17, 2010, The Lancet Oncology, online


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Kings College London reveals promising techniques for extending the life of an organ transplant
2. Promising treatment for metastatic melanoma fast tracked by FDA
3. A promising target for developing treatments against Parkinsons disease
4. Natural lung material is promising scaffold for engineering lung tissue using embryonic stem cells
5. Depression overlooked in patients with hepatitis C; compromising HCV therapy
6. BRAF inhibitor shows promising preclinical activity against melanoma
7. New promising therapy against systemic sclerosis
8. Is the current recession compromising hospital quality?
9. Peaches, plums induce deliciously promising death of breast cancer cells
10. U of A discovery offers promising research for spinal-cord injury treatments
11. Study identifies promising treatment for aggressive lymphoma
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
New Drug Promising for Advanced Thyroid Cancer
(Date:3/27/2017)... ... March 27, 2017 , ... ... -centric training, today announced the launch of a new research study, The Business ... skills needed to execute that strategy, and the actual success of achieving individual ...
(Date:3/27/2017)... ... , ... According to the American Cancer Society , the average 15-year ... Once the cancer spreads to other organs, bones, or lymph nodes, however, the 5-year ... this latter group, tune in to Lifestyle Magazine on April 9, 2017, ...
(Date:3/27/2017)... ... 2017 , ... Golden Triangle Emergency Center will be hosting ... to commemorate the two-year anniversary of the facility. The event will feature refreshments ... years while also familiarizing themselves with the facility. , In the two years ...
(Date:3/25/2017)... ... 2017 , ... Getting earned media coverage meaningful for Garden Media Group's clients ... the year, Garden Media aims to provide material helpful to clients’ goals and bottom ... client’s key messages to gain coveted media placements, Garden Media wows clients year-round. ...
(Date:3/24/2017)... ... March 24, 2017 , ... Infectious disease ... hospitals in the United States, it’s a threat that is constantly changing and ... infection prevention and offers strategies for the healthcare community to help decrease the ...
Breaking Medicine News(10 mins):
(Date:3/27/2017)... , March 27, 2017  A recent study ... only four freestanding hospitals in the country dedicated to ... and reconstructive surgery, concluded that the Surfacide Helios ® ... integral component in reducing bacterial pathogens not killed by ... were published at the American Burn Association,s 49th Annual ...
(Date:3/27/2017)... 27, 2017 LightIntegra Technology Inc. today announced ... Dubiel as President and Chief Executive Officer effective March ... Board of Directors of LightIntegra. Paul Geyer ... LightIntegra. "This is the perfect time ... Executive Officer. We,ve selected a very strong leader at ...
(Date:3/27/2017)... , March 27, 2017  Sanderling Ventures, portfolio ... Ethicon, a division of Johnson & Johnson. Torax manufactures ... the treatment of gastro-esophageal reflux disease (GERD). The ... (MSA) technology and the procedure is currently available ... Torax Medical was founded by Sanderling Ventures, ...
Breaking Medicine Technology: